Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Glioma
Interventions: Temozolomide and Bevacizumab; Drug
Lead sponsor: Kentuckiana Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Melanoma
Interventions: High dose bolus interleukin-2 (HD IL2); Drug
Lead sponsor: Ahmad Tarhini; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Dedifferentiated Liposarcoma
Interventions: DCC-3014, Avelumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions: Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neoplasms
Interventions: Rivaroxaban, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 70
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more

Conditions: Human Immunodeficiency Virus
Interventions: Social Network, Brief HIV Prevention Counseling; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 16 Years and older · Male only
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Cleveland, Ohio • Milwaukee, Wisconsin

Conditions: Autism, Autism Spectrum Disorder, Autistic Disorder, Autism, Akinetic, Autism; Atypical, Autism; Psychopathy, Autism Fragile Syndrome X, Autism With High Cognitive Abilities, Autism-Related Speech Delay, Autism, Susceptibility to, 6, Autism Spectrum Disorder High-Functioning, Autistic Thinking, Autism, Susceptibility to, X-Linked 6, Autistic Behavior
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 6 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Altitude, Hypoxia, Environmental Sleep Disorder
Interventions: altitude exposure in hypobaric chamber; Procedure
Lead sponsor: Oklahoma State University Center for Health Sciences; Other
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
Interventions: Fimepinostat, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 3 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 15 more

Conditions: Coronary Artery Disease
Interventions: Clopidogrel; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cervical Intraepithelial Neoplasia
Interventions: PepCan, Candin®; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Obstructive Sleep Apnea
Interventions: High-resolution pharyngeal manometry catheter; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiovascular Risk
Interventions: CLAiR Artificial Intelligence Software; Device
Lead sponsor: Toku Eyes Ltd; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Homer Glen, Illinois • Canton, Ohio

Conditions: Traumatic Brain Injury
Interventions: Physical therapy; Other
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Head and Neck Cancer
Interventions: filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14; Biological · Drug · Procedure + 1 more
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 16 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 2
States / cities: Belleville, New Jersey • Paterson, New Jersey

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma
Interventions: temozolomide; Drug
Lead sponsor: Duke University; Other
Eligibility: 4 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Obesity
Interventions: Mediterranean diet, Olive oil and mixed nuts, American Heart Association; Behavioral · Dietary Supplement
Lead sponsor: Auburn University; Other
Eligibility: 19 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
Interventions: imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis; Drug · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 21 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Obesity
Interventions: High-Intensity Functional Training, Army Physical Readiness Training; Behavioral
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Leavenworth, Kansas • Manhattan, Kansas

Conditions: Melanoma
Interventions: T-Vec; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Glioblastoma, Anaplastic Astrocytoma, Astrocytoma, Anaplastic Oligodendroglioma
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Interventions: High Intensity Rehabilitation, Safe Transfers and Mobility Program, Usual Care; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Frisco, Texas

Conditions: Pre-Exposure Prophylaxis (PrEP), Breast Feeding
Interventions: Cabotegravir Injection [Apretude]; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors
Interventions: incyclinide; Drug
Lead sponsor: New Approaches to Brain Tumor Therapy Consortium; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Search by objective public record fields.

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

HSCT for High Risk Inherited Inborn Errors

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Autism

Effects of Mild Hypobaric Hypoxia on Sleep and Post-sleep Performance

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Pilot Study on the Effect of High Clopidogrel Maintenance Dosing

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

Pharyngeal Anatomy In Obstructive Sleep Apnea With HRM

Precision Study of CLAiR AI Software

High Intensity Step Training After Traumatic Brain Injury

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors

A Mediterranean Diet Nutrition Education Program for the Reduction of Cardiovascular Disease Risk in the Southeastern U.S.

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Army Training at High Intensity Study

Neoadjuvant T-VEC in High Risk Early Melanoma

Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

Supplemental Mobility

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors